New Hampshire Trust Sells 639 Shares of Bristol-Myers Squibb (NYSE:BMY)

New Hampshire Trust lessened its holdings in Bristol-Myers Squibb (NYSE:BMYFree Report) by 5.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,070 shares of the biopharmaceutical company’s stock after selling 639 shares during the quarter. New Hampshire Trust’s holdings in Bristol-Myers Squibb were worth $772,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Cigna Investments Inc. New raised its stake in Bristol-Myers Squibb by 0.5% during the 4th quarter. Cigna Investments Inc. New now owns 26,379 shares of the biopharmaceutical company’s stock valued at $1,898,000 after purchasing an additional 141 shares during the period. Catalyst Financial Partners LLC raised its stake in Bristol-Myers Squibb by 2.5% during the 1st quarter. Catalyst Financial Partners LLC now owns 6,001 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 145 shares during the period. Keystone Wealth Services LLC raised its stake in Bristol-Myers Squibb by 2.0% during the 1st quarter. Keystone Wealth Services LLC now owns 7,468 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 148 shares during the period. Dillon & Associates Inc. raised its stake in Bristol-Myers Squibb by 3.9% during the 1st quarter. Dillon & Associates Inc. now owns 3,955 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 150 shares during the period. Finally, Abbrea Capital LLC raised its stake in Bristol-Myers Squibb by 1.5% during the 1st quarter. Abbrea Capital LLC now owns 10,025 shares of the biopharmaceutical company’s stock valued at $695,000 after purchasing an additional 150 shares during the period. Institutional investors own 74.98% of the company’s stock.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $61.25, for a total value of $1,101,642.50. Following the completion of the transaction, the executive vice president now directly owns 27,868 shares of the company’s stock, valued at approximately $1,706,915. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $61.25, for a total value of $1,101,642.50. Following the completion of the transaction, the executive vice president now directly owns 27,868 shares of the company’s stock, valued at approximately $1,706,915. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Robert M. Plenge sold 732 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total value of $44,754.48. Following the completion of the transaction, the executive vice president now directly owns 6,584 shares of the company’s stock, valued at $402,545.76. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.8 %

BMY traded down $0.46 during trading hours on Friday, reaching $59.03. 22,379,176 shares of the company’s stock traded hands, compared to its average volume of 8,954,007. The company has a quick ratio of 1.28, a current ratio of 1.39 and a debt-to-equity ratio of 1.08. The firm has a 50-day moving average price of $61.62 and a 200 day moving average price of $65.14. The firm has a market capitalization of $123.32 billion, a PE ratio of 15.70, a PEG ratio of 1.58 and a beta of 0.42. Bristol-Myers Squibb has a 52-week low of $58.86 and a 52-week high of $81.43.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.24). The firm had revenue of $11.23 billion for the quarter, compared to the consensus estimate of $11.81 billion. Bristol-Myers Squibb had a net margin of 17.62% and a return on equity of 50.51%. The company’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same period last year, the firm earned $1.93 earnings per share. As a group, sell-side analysts predict that Bristol-Myers Squibb will post 7.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BMY. Morgan Stanley reissued an “underweight” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, July 19th. BMO Capital Markets cut their price target on Bristol-Myers Squibb from $87.00 to $79.00 and set an “outperform” rating for the company in a report on Friday, July 28th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, September 1st. Atlantic Securities cut their price target on Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, July 28th. Finally, HSBC started coverage on Bristol-Myers Squibb in a report on Friday, July 14th. They set a “reduce” rating and a $56.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $70.67.

Check Out Our Latest Analysis on Bristol-Myers Squibb

About Bristol-Myers Squibb

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Further Reading

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.